Soquelitinib

SKU: orb2565260

Description

Soquelitinib (CPI-818) is an oral, covalent inhibitor of ITK that selectively reduces Th2 cytokine production. It demonstrates anti-tumor activity in mouse models by modulating T-cell function, reducing exhaustion markers, and enhancing tumor infiltration alongside the upregulation of CXCR3, IFNγ, and CD107a in CD8+ T cells. This profile supports its research use in immunology and oncology for studying T-cell-mediated responses.

Research Area

Cell Biology, Immunology & Inflammation, Neuroscience, Pharmacology & Drug Discovery, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	2226636-04-8
MW	514.66
Purity	99.54%
Formula	C₂₅H₃₀N₄O₄S₂
SMILES	C(=O)(C1=C(OC)C=C(C)C(SC=2SC(NC(=O)C3CC3)=NC2)=C1)N4C[C@@H](C)N(C(C=C)=O)CCC4
Target	Tyrosine Kinases,CXCR,COX,TNF,IL Receptor,Immunology/Inflammation related
Solubility	DMSO:80 mg/mL (155.44 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:10 mg/mL (19.43 mM)

Bioactivity

−

Target IC50	IL-2 secretion (Jurkat T cells):136 nM
In Vivo	Oral administration of soquelitinib (30 mg/kg, b.i.d.) significantly inhibited tumor growth in multiple murine tumor models (CT26, RENCA, B16F10, EL4, A20). Soquelitinib enhanced CD8+ T-cell infiltration and cytotoxic activity (e.g., increased IFNγ, TNF, Perforin). Combined treatment with anti-PD-1 or CTLA-4 antibodies showed synergistic effects, with complete tumor regression in some cases and reduced expression of exhaustion markers in TILs. Long-term oral dosing in rats showed no observable toxicity (NOAEL >1000 mg/kg). Read more...
In Vitro	In Jurkat T cells, Soquelitinib inhibits downstream TCR signaling (e.g., phosphorylation of PLCγ1 and ERK) and suppresses IL-2 secretion (IC₅₀ = 136 nM). Soquelitinib downregulates Th2 cytokines (IL-4, IL-5, IL-13) and promotes Th1 skewing. In repeatedly stimulated human CD8 T cells, 1 μM soquelitinib reduces exhaustion markers (PD1, LAG3, TIGIT, Tim3) and restores effector functions, increasing IFNγ and Granzyme B levels. Read more...

Storage & Handling

−

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

CPI818, CPI-818

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

134517711 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Soquelitinib (orb2565260)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Soquelitinib

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Soquelitinib (orb2565260)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors